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This article examines the Organ Procurement and
Transplantation Network/Scientific Registry of Trans-
plant Recipients data on heart and lung transplanta-
tion in the United States from 1996 to 2005. The num-
ber of heart transplants performed and the size of the
heart waiting list continued to drop, reaching 2126
and 1334, respectively, in 2005. Over the decade, post-
transplant graft and patient survival improved, as did
the chances for survival while on the heart waiting list.
The number of deceased donor lung transplants in-
creased by 78% since 1996, reaching 1407 in 2005 (up
22% from 2004). There were 3170 registrants await-
ing lung transplantation at the end of 2005, down 18%
from 2004. Death rates for both candidates and recipi-
ents have been dropping, as has the time spent waiting
for a lung transplant. Other lung topics covered are liv-
ing donation, recent surgical advances and changes in
immunosuppression regimens. Heart-lung transplan-
tation has declined to a small (33 procedures in 2005)
but important need in the United States.
Key words: SRTR, OPTN, heart transplantation, lung
transplantation, graft survival, patient survival
Introduction
This article describes the state of affairs in thoracic organ
transplantation in the United States over the last decade.
While there have always been differences of opinion re-
garding organ utilization and distribution, the focus of these
last 10 years has been toward reducing waiting list deaths,
while improving allocation to enhance outcomes. The fruits
of the labors of the Organ Procurement and Transplanta-
tion Network’s (OPTN) Thoracic Committee and advanced
analyses by the Scientific Registry of Transplant Recipients
(SRTR) have yet to be fully realized, but there are now poli-
cies in place that distribute lungs based on need balanced
by predicted outcome, and a new heart policy that en-
courages broader geographic sharing of organs and is pre-
dicted to reduce waiting list deaths. The changes brought
by these new policies will be watched closely for equity
and fairness, with the ongoing intention of maintaining a
system that is aimed at patient need. Exciting new, and
sometimes preliminary, information is discussed below.
Heart
Heart waiting list characteristics
The waiting list characteristics presented here represent
potential transplant recipients on the waiting list at the end
of each calendar year from 1996 to 2005 (Table 1). The total
number of patients active on the heart waiting list contin-
ued to decline during this time period to an all-time low
of 1334, a 45% reduction since 1996. This reduction was
most prominent in transplant candidates with a coronary
artery disease classification (a 53% reduction, Figure 1)
and in the age range of 35–64 (Figure 2). The reduced size
of the heart waiting list may reflect better outcomes from
improvements in medical, interventional and surgical treat-
ments of coronary disease.
The number of white patients, relative to other ethnicity
categories, has seen a 51% reduction since 1996. A much
less dramatic decrease of 23% was observed in African
Americans (Figure 3). The percentage of patients waiting
with blood type O has increased by approximately 9% and
the percentage of females waiting has increased by ap-
proximately 5%. Other characteristics, such as country of
residence, have remained relatively unchanged over time
(98.9–99.9% of patients were U.S. residents in every year
since 1996).
There has been an increasing proportion of Status 1B pa-
tients since 2000 (18% in 2000 to 24% in 2005) with a
corresponding decrease in the proportion of Status 2 pa-
tients listed (79% in 2000 to 70% in 2005). Status 1A has
remained generally stable over time (Figure 4). This indi-
cates a relatively large shift in patients from the more stable
Status 2 to Status 1B.
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Patients listed as active at end of each year.
The rules for listing as Status 1A include a high risk of
dying within 7 days of listing, having a ventricular assist
device (VAD) in place (limited to 30 days), or having VAD
complications such as infection or being on mechanical
ventilatory support. As of January 1, 2005, 26% of patients
listed as Status 1A were still listed as Status 1A at the
end of 30 days. Though patients were to be limited to a
maximum of 30 days at Status 1A, at 60 days 12% were
still listed as Status 1A and at 90 days there were 10% still
listed.
Definitions for each status group are as follows: A Sta-
tus 1A candidate has either mechanical circulatory support
for acute hemodynamic decompensation, support with ob-
jective medical evidence of device-related complications,
continuous mechanical ventilation or continuous infusion
of intravenous inotropes, in addition to continuous mon-
itoring of left ventricular filling pressures. Additionally, a
patient may be listed as Status 1A in the absence of these
conditions if the transplant physician submits an applica-
tion for status to the applicable Regional Review Board for
review and the application is subsequently approved. The
decision of the Regional Review Board is also reviewed by
the OPTN Thoracic Organ Transplantation Committee. A
Status 1B candidate has a left and/or right VAD implanted
and/or continuous infusion of intravenous inotropes. A can-
Source: 2006 OPTN/SRTR Annual Report, Table 11.1a.
Figure 1: Primary diagnoses of patients active on the heart
waiting list at year-end, 1996–2005.
Source: 2006 OPTN/SRTR Annual Report, Table 11.1a.
Figure 2: Age distribution of patients active on the heart wait-
ing list at year-end, 1996–2005.
didate not meeting the conditions for Status 1A or Status
1B may be listed as Status 2.
Deaths on the heart waiting list
Overall numbers and death rates in patients awaiting heart
transplantation have been declining over the last 10 years
from a death rate of 227 per 1000 patient-years at risk
in 1996 to 152 in 2005 (Figure 5), likely a result of im-
proved medical therapy and mechanical support for pa-
tients with advanced heart failure. This trend was evident
across all ethnic, gender and blood type groups. It was
also evident across all age groups except for ages <1
year, where the death rate in 2005 was higher than in
any of the previous 9 years (109 patients in 2005 with
30 deaths).
Death rates have decreased sharply among Status 1A
candidates from 2000 to 2005 (2087 vs. 1580 deaths
per 1000 patient-years at risk). Death rates among
Source: 2006 OPTN/SRTR Annual Report, Table 11.1a.
Figure 3: Race of patients active on the heart waiting list at
year-end, 1996–2005.
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∗Data prior to 2000 not shown due to change in status categories.
Source: 2006 OPTN/SRTR Annual Report, Table 11.1a.
Figure 4: Status of patients active on the heart waiting list at
year-end, 2000–2005.
Status 1B and Status 2 patients have declined less sharply
(Figure 6).
Heart transplant recipient characteristics
The overall number of heart transplants has declined by 9%
over the last 10 years (2343 performed in 1996 to 2126 in
2005). There has also been a 19% decrease in the inci-
dence rate of transplant per million U.S. residents (Figure
7). Similar to changes in listing patterns, these reductions
in transplants primarily occur in patients aged 35–64 and
in patients with coronary artery disease, likely reflecting
improvement in the medical and surgical management of
patients with this disease (1–5). Patients <18 years have
seen an increase of approximately 20% and 5% for number
and incidence per million, respectively. Patients between
the ages of 18 and 34 have seen increases of 26% and
18%, respectively (Figure 8).
Source: 2006 OPTN/SRTR Annual Report, Table 11.3.
Figure 5: Annual death rate of patients awaiting heart trans-
plantation, per 1000 patient-years at risk, 1996–2005.
∗Data prior to 2000 not shown due to change in status categories
Source: 2006 OPTN/SRTR Annual Report, Table 11.3.
Figure 6: Annual death rates per 1000 patient-years on the
heart waiting list by status, 2000–2005.
The number of transplants received by whites has de-
creased over time, while there has been an increase for
the other ethnic categories (Figure 9). The proportion of
transplants given to males relative to females has been
relatively stable over the last 10 years, with males contin-
uing to receive approximately 75% of heart transplants.
The waiting list status of heart transplant recipients at the
time of transplantation has changed little since the incep-
tion of the new classification system in 1999. The percent-
age of heart transplant recipients who were Status 1A, 1B
and 2 at the time of transplantation has been approximately
40%, 35% and 25%, respectively. This is likely to change in
the future, with wider geographic sharing of donor hearts
for candidates who are Status 1A or 1B. As approved by
the OPTN Board of Directors in November 2005 (and as de-
scribed below) (6), the policy shift toward broader sharing
Source: 2006 OPTN/SRTR Annual Report, Table 11.4 and 11.5.
Figure 7: Number of heart transplants and incidence of trans-
plant per million population, 1996–2005.
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Source: 2006 OPTN/SRTR Annual Report, Table 11.4.
Figure 8: Age of heart transplant recipients, 1996–2005.
is expected to lead to a decrease in Status 2 transplants in
favor of sicker candidates.
Immunosuppression therapy for heart transplantation
The immunosuppression regimen for heart transplantation
has continued to evolve over the past decade. Induction
therapy was used in 31% of patients in 1996, and has grad-
ually increased to 52% in 2005.
With respect to induction therapy agents, there has been
a gradual decline in the use of anti-lymphocyte antibodies
since 1996. Most transplanted patients in 2005 received
either rabbit anti-thymocyte globulin (15%: Thymoglobu-
lin®, SangStat Medical Corp., Fremont, CA), daclizumab
(15%: Zenapax®, Roche, Nutley, NJ) and/or basiliximab
(14%: Simulect®, Novartis, East Hanover, NJ). In 2005,
triple drug combination therapies were the norm at 1 year
after transplantation. Cyclosporine (CyA) or Tacrolomus
(Tac) (Prograf®, Astellas Pharma US, Deerfield, IL) plus My-
cophenolate Mofetil/Mycophenolate Sodium (MMF/MPA)
Source: 2006 OPTN/SRTR Annual Report, Table 11.4.
Figure 9: Race of heart transplant recipients, 1996–2005.
Table 2: Immunosuppression usage rates in 1995 and 2004 from
discharge to 1-year posttransplantation for heart recipients
Year of transplant
1995 2004
Number of transplants 2363 2016













Any in category 89.2% 94.3%
Mycophenolate mofetil 11.8% 83.9%





Any in category 0.0% 12.8%
Sirolimus 0.0% 12.8%
Everolimus 0.0% 0.1%
Source: OPTN/SRTR 2006 Annual Report.
(Cellcept®, Roche, Nutley, NJ) plus steroids were the two
most common regimens used in patients, respectively
(Table 2).
A notable trend is the declining number of recipients who
needed treatment for rejection episodes during the first
year following transplantation (25% in 2004 compared
to 40% in 1995). The decline probably reflects the im-
proved efficacy of the newer immunosuppression medica-
tions, but also may be due to incremental improvements
in the overall care of the donor and recipient. Concurrent
trends on the incidence of infection and malignancy de-
serve study.
Heart transplant outcomes
Deaths in the first year after heart transplantation have
steadily decreased from 171 deaths per 1000 patient-years
at risk in 1996 to 133 in 2004 (Figure 10). Adjusted to the
characteristics of the 1995 heart transplant population (ad-
justed for age, gender, race and diagnosis of the 1995 pop-
ulation so that comparisons can be made across years),
patient survival at 3 months and 1 year has also improved
from 1996 percentages of 90% and 85% to 2004 percent-
ages of 93% and 88%, respectively. Long-term survival
has increased at 3 and 5 years from 77% and 71%, re-
spectively, in 1996 to 79% and 76% in 2001, the most
recent year with adequate post-transplant follow-up. Ad-
justed graft survival was nearly identical to adjusted patient
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Source: 2006 OPTN/SRTR Annual Report, Table 11.7.
Figure 10: Annual death rate per 1000 patient-years at risk, for
recipients during first year after heart transplantation, 1996–
2004.
survival, with adjustments for graft survival based on the
age, race, gender and diagnosis characteristics of trans-
plants in 1995.
The prevalence of people living with a functioning heart
allograft at the end of each year increased from 12 827
in 1996 to 17 329 in 2004. These results translate across
ethnicity, gender, blood type, primary diagnosis, or waiting
list status at the time of transplantation and are a testament
to advances in the medical and surgical therapies for end-
stage heart disease and post-transplant care.
There is variability in how post-transplant death rates have
declined since 1996. The downward trajectory of 1-year
death rates is more marked among African Americans and
Hispanics and brings them more into line with 1-year death
rates of whites (Figure 11), although African Americans ex-
perience somewhat worse survival starting at 3-years post-
transplant relative to the other ethnicity groups (Figure 12).
Downward trends in death rates have had more year-to-
Source: 2006 OPTN/SRTR Annual Report, Table 11.7.
Figure 11: Annual death rate per 1000 patient-years at risk,
for recipients during first year after heart transplantation, by
race, 1996–2004.
∗Adjusted to the characteristics of the 3 month/1 year cohort
(2003-04 transplants)
Source: 2006 OPTN/SRTR Annual Report, Table 11.12.
Figure 12: Adjusted∗ heart recipient survival by race, 1996–
2004.
year variability among the smaller number of Asian trans-
plant recipients. Death rates for females versus males have
declined 4% versus 29% since 1996 and women continue
to have a slightly worse survival experience over time, with
approximately 2% lower survival percentages than males
at the same point post-transplant. Congenital heart disease
patients have seen lower post-transplant survival than for
coronary artery disease, valvular and cardiomyopathy pa-
tients (Figure 13). There is also a greater decline among Sta-
tus 1A patients compared to the other status categories,
since 1999, bringing their post-transplant death rates more
in line with Status 1B patients (Figure 14).
In 2004, annual death rates per 1000 patient-years at risk
during the first year after transplantation remained high-
est for those <1-year old or those 65 years or older, with
death rates of 228 and 198, respectively. A 1-year death
∗Adjusted to the characteristics of the 3 month/1 year cohort
(2003-04 transplants)
Source: 2006 OPTN/SRTR Annual Report, Table 11.12.
Figure 13: Adjusted∗ heart recipient survival, by diagnosis,
1996–2004.
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∗Data prior to 2000 not shown due to change in status categories
Source: 2006 OPTN/SRTR Annual Report, Table 11. 7.
Figure 14: Annual death rate per 1000 patient-years at risk,
during first year after heart transplantation, by status, 2000–
2004.
rate of 62.9 per 1000 patient-years at risk set a new 10-
year low for patients aged 11–17 in 2004. The 2004 death
rate during the first year after transplantation was 37%
higher in females versus males (165 vs. 130, respectively).
By diagnosis from highest to lowest, the death rates in
2004 were 266 for congenital heart disease, 216 for valvu-
lar heart disease, 140 for coronary heart disease and 102
for cardiomyopathy.
Heart allocation policy changes
In 1998, in response to public inquiry concerning the equi-
table allocation of donor organs, the Health Resources and
Services Administration of the United States Department
of Health and Human Services published a revision to the
OPTN Final Rule (7). It was the intent of the Final Rule
to not only ensure broad geographic sharing and equitable
distribution of organs, but to also minimize discrepancies in
waiting times across regions. Implementation of the Final
Rule in 2000 required a complete reevaluation of the na-
tion’s organ allocation policies. The responsibility for that
reevaluation ultimately devolved upon the various OPTN
committees and subcommittees.
In 2004, the OPTN Thoracic Organ Transplantation Com-
mittee began to consider various proposals brought forth
by the SRTR. The long-term intent of the proposals was to
change the allocation system from one based upon waiting
time and listing-center-defined medical urgency statuses
(1A, 1B or 2) to an allocation system based upon more
data-driven estimates of medical urgency and transplant
benefit. The concept was not new, having been previously
adopted in February 2002 by the liver transplant commu-
nity and more recently adopted by the lung transplant com-
munity, which subsequently implemented their new lung
allocation score (LAS) in May 2005. Draft models are cur-
rently being built for heart waiting list and posttransplant
patients for use in a new heart allocation score that would
replace status 1A, 1B and 2 designations.
The SRTR also provided data to assess current geographic
policies for heart allocation based on status. Traditionally,
hearts were allocated locally before being offered out to
the region. The natural consequence of this policy was
that a Status 2 candidate registered on the local organ pro-
curement organization’s (OPO) waiting list would receive a
heart prior to a Status 1A or 1B candidate waiting outside
of the OPO. Recent studies, however, have demonstrated
that transplantation is of marginal early benefit in Status 2
candidates (8).
In view of this information, the OPTN Thoracic Organ Trans-
plantation Committee, in conjunction with the SRTR, as-
sessed the impact of moving Zone A 1A and 1B patients
ahead of local Status 2 patients, using the thoracic simu-
lation allocation model (TSAM) to develop an allocation al-
gorithm that would improve the availability of organs for
those candidates who are truly the sickest (Figure 15).
Using data already available, simulation modeling allows
one to predict the effect on an allocation policy change on
the number of transplants and deaths, before implement-
ing the policy. While some OPTN regions initially opposed
the change, expressing concern that the new distribution
scheme would disproportionately impact smaller centers
situated near larger centers, the Committee nevertheless
felt that the global benefit, in terms of lives saved as indi-
cated by TSAM, outweighed the possible risk to the smaller
centers.
In contrast to the new allocation system for lung transplan-
tation, which uses a combination of risk factors to estimate
urgency and the ‘net benefit’ as a result of transplanta-
tion, the new heart algorithm which was implemented in
July 2006 continues to use the existing status categories
to capture urgency and transplant benefit and instead fo-
cuses on changes to geographic distribution. In particular,
as compared to the prior system, once local 1A and 1B
Source: SRTR Analysis, May 2005.
Figure 15: TSAM results comparing heart transplants from
the four allocation policies by status, 2002.
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Source: SRTR Analysis, May 2005.
Figure 16: TSAM heart transplant results from the four allo-
cation policies by zone, 2002.
candidates are exhausted, the organ is offered to Zone A
(centers within 500 miles), Status 1A and 1B candidates
before being offered back to local centers for Status 2 can-
didates (Figure 16). TSAM has repeatedly demonstrated a
global decrease in the number of waiting list deaths and
total deaths, and an increase in the number of transplants
with this approach (Figures 15 and 17).
Clearly, as TSAM predicts, the number of Status 2 patients
undergoing transplantation is expected to decrease signif-
icantly. The decrease, however, should be offset by an in-
crease in Status 1A and 1B transplants. This is confirmed by
SRTR simulation models. Using the 2002 heart transplant
cohort, under the new allocation algorithm Status 2 trans-
plants would have decreased from 539 to 210 (Figure 15).
In contrast, Status 1A transplants would have increased
Source: SRTR Analysis, May 2005.
Figure 17: Total Deaths Predicted by TSAM, by Allocation
Policy, 2002.
from 879 to 1044 while Status 1B transplants would have
increased from 707 to 895. In all, total heart waiting list
deaths would have decreased from 562 to 513 and total
deaths from 868 to 819 (SRTR analysis, May 2005). Ad-
mittedly, how this change will affect any individual center
is difficult to know. While fewer Status 2 patients will be
transplanted at any given center, the number of Status 1A
and 1B candidates transplanted should increase as a result
of additional imported organs.
For the new scheme to work equitably, programs must
be confident that Status 1A (1A(e) in particular) and 1B
patients are listed using consistent criteria. This is neces-
sary to ensure that large centers in Zone A do not dispro-
portionately affect neighboring regions by inappropriately
listing patients as 1A or 1B who do not technically meet
the criteria. The Committee recognized this concern and
responded by developing a new listing form which will ini-
tially be used for Status 1A(e) patients. It is hoped that
via this mechanism the Regional Review Boards will have
more information available to make certain that the patient
meets the criteria for 1A(e). It is anticipated that in due
time additional data will also be collected for status 1A(d)
listings as well.
Table 3: Sequence of adolescent heart allocation
Sequence Patients
1 Local Status 1 pediatric patients
2 Zone A Status 1A pediatric patients
3 Local Status 1A adult patients
4 Local Status 1B pediatric patients
5 Zone A Status 1B pediatric patients
6 Local Status 1B adult patients
7 Zone A Status 1A adult patients
8 Zone A Status 1B adult patients
9 Local Status 2 pediatric patients
10 Local Status 2 adult patients
11 Zone B Status 1A pediatric patients
12 Zone B Status 1A adult patients
13 Zone B Status 1B pediatric patients
14 Zone B Status 1B adult patients
15 Zone A Status 2 pediatric patients
16 Zone A Status 2 adult patients
17 Zone B Status 2 pediatric patients
18 Zone B Status 2 adult patients
19 Zone C Status 1A pediatric patients
20 Zone C Status 1A adult patients
21 Zone C Status 1B pediatric patients
22 Zone C Status 1B adult patients
23 Zone C Status 2 pediatric patients
24 Zone C Status 2 adult patients
25 Zone D Status 1A pediatric patients
26 Zone D Status 1A adult patients
27 Zone D Status 1B pediatric patients
28 Zone D Status 1B adult patients
29 Zone D Status 2 pediatric patients
30 Zone D Status 2 adult patients
Source: OPTN.
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Source: 2006 OPTN/SRTR Annual Report, Tables 1.3 and 12.1a.
Figure 18: Active versus inactive lung waiting list patients at
year-end, 1996–2005.
The pediatric heart transplant community expressed con-
cerns that the new allocation algorithm would dispropor-
tionately jeopardize Status 2 pediatric candidates. While
adult Status 2 patients can be adequately managed medi-
cally and may not derive early benefit from transplantation,
similar data are not available for the pediatric population
due to the smaller numbers. For this reason, the OPTN
Thoracic Organ Transplantation Committee elected to treat
the pediatric population differently, and continued with the
local allocation first policy (Table 3).
Other changes of note that occurred over the past 12
months include modifications of UNOS Policy 3.7.3 (Adult
Candidate Status). Effective in mid-2006, the requirement
that left VAD recipients with device infections be admit-
ted as an inpatient at the listing center in order to remain
Status 1(A)(b) has been deleted. (VAD patients with a his-
tory of a thromboembolism, device-related complications
and/or malignant arrhythmias will still need to be admitted
to the listing center to remain a Status 1(A) candidate.)
In addition, heart transplant candidates insured through
the Veterans Administration system may now remain
at a Veterans Administration facility and stay listed as
Status 1A.
Another change to the allocation scheme went into effect
July 12, 2006. Now, not only are hearts allocated to Zone
A, Status1A and 1B patients before local Status 2, but all
alternative allocation systems were also dissolved, in the
interest of broader geographic sharing. A task force es-
tablished by the UNOS Board of Directors to oversee the
modifications in policy and to evaluate efficacy will follow
this change closely.
Lung
Lung waiting list characteristics
At the end of 2005, there were 3170 registrants awaiting
lung transplantation, an 18% drop from the 2004 count of
3870. An even sharper drop of 51% was seen in active pa-
tients on the lung waiting list; from 2164 in 2004 to 1053 in
Source: 2006 OPTN/SRTR Annual Report, Tables 12.1a.
Figure 19: Age distribution of active lung waiting list at year-
end, 1996–2005.
2005 (Figure 18). These decreases likely reflect changes in
listing practices in response to the implementation in May
2005 of the new lung allocation policy, based on survival
benefit and urgency rather than waiting time.
The age of active patients on the lung waiting list has
changed over the past decade (Figure 19), with the per-
centage of patients over 50 increasing from 43% in 1996
to 55% in 2005, the percentage of patients 18–50 dropping
from 51% in 1996 to 37% in 2005, and the percentage of
patients 18 years and younger increasing from 6% to 7%.
Most of these distributional shifts had already taken place
over the 9 years before implementation of the new lung
allocation policy, with only relatively small changes in the
distribution between 2004 and 2005. In spite of the small
changes in the age distribution between 2004 and 2005,
the large change in actual numbers of patients active on
the waiting list described above was not consistent over all
age groups. The number of patients less than 11 remained
fairly stable between 2004 and 2005, while the number
of older patients dropped by 52%. This difference is most
likely because of the change in lung allocation policy which
only applies to patients aged 12 and above; lungs are still
allocated on the basis of waiting time to children under
age 12.
The diagnosis distribution changed notably between 2004
and 2005, with the most dramatic shift in idiopathic pul-
monary fibrosis (IPF) patients, who represented 18% of
the active lung waiting list at the end of 2004 but only 12%
at the end of 2005 (Figure 20). This change reflects, in part,
a relative increase in the number of IPF transplants under
the new policy (28% of lung transplants in 2005 vs. 24%
in 2004).
The gender and ethnic makeup of the active waiting list
changed somewhat between 2004 and 2005. At the end
of 2005 the percentage of waiting females, 60%, was the
highest observed in 10 years, up from 55% at the end of
2004, while the percentage of African American patients
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dropped from 10% to 8% during that time. In 2005, active
waiting list patients were most commonly female (60%),
white (85%), blood type O (50%) and had not received a
previous transplant (97%).
In 2005, relatively fewer patients chose to become inac-
tive if they had been waiting 2 years or more. In listing
two or more years prior, these patients were likely count-
ing on having an organ placement under the old allocation
system. The percentage of inactive patients increased in
2005 compared to 2001–2005.
The time by which 25% of newly listed candidates have
received a transplant (25th percentile), overall by year of
registration, reached a 10-year low of 54 days in 2005
compared to 183 days in 2004 (Figure 21), and the me-
dian time to transplant reached a 10-year low of 202 days
in 2005. This substantial decrease in time to transplant is
a combination of administrative efficiency of lung place-
ment as well as an increase in available organs due to
fewer discards under the new system. Time to transplant
was shorter in all age groups, ethnic groups, blood type
groups and in both males and females, in 2005 compared to
2004.
Deaths on the lung waiting list
Death rates among waiting list patients have decreased by
45% over the past decade from 207 per 1000 patient-years
at risk in 1996 to 114 per 1000 patient-years at risk in 2005
(Figure 22). Twenty-three percent of this rate decrease was
observed between 2004 and 2005.
Although the trend for females to have a slightly lower
death rate than males continued in 2005 (112 compared
to 117 per 1000 patient-years at risk), the discrepancy was
much smaller in 2005 than in the previous 9 years. This
change is observed at a time when the percentage of
women receiving a lung reached a 10-year low in 2005
at 45%.
Source: 2006 OPTN/SRTR Annual Report, Tables 12.1a.
Figure 20: Primary diagnoses of patients active on the lung
waiting list, 1996–2005.
Source: 2006 OPTN/SRTR Annual Report, Tables 12.2.
Figure 21: Time to transplant for lung registrants, 25th per-
centile, 1996–2005.
Hispanic patients had much higher death rates than whites,
African Americans or Asians (237 compared to 103, 135,
and 135 per 1000 patient-years at risk, respectively). Im-
provements in death rates between 2004 and 2005 were
observed primarily in white patients, despite a similar dis-
tribution of transplanted organs by race between 2004 and
2005 and an only slightly shifted distribution of actively
listed patients by race between these years. It will be im-
portant to watch this dynamic during the next year to see
if this pattern evens out.
Patients aged 18–34 years and those 65 years and older
had the highest death rates in 2005 (152 and 151 per
1000 patient-years at risk, respectively), while those aged
35–49 had the lowest death rates in 2005 (87 per 1000
patient-years at risk). The improvements in the death rate
between 2004 and 2005 were most evident in those older
than 35.
Lung transplant recipient characteristics
The number of deceased donor lung transplants has in-
creased by 78% over the past decade, from 791 in 1996 to
1407 in 2005. The 2005 number represents a fairly sharp
increase from the 1157 performed in 2004 (Figure 23),
before implementation of the new lung allocation system
Source: 2006 OPTN/SRTR Annual Report, Tables 12.3.
Figure 22: Annual death rate of patients on the lung waiting
list, per 1000 patient-years at risk, 1996–2005.
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Source: 2006 OPTN/SRTR Annual Report, Tables 12.4.
Figure 23: Number of deceased donor lung transplants,
1996–2005.
and the early stages of the Organ Donation Breakthrough
Collaborative. Although all age groups older than 1 year
have seen at least some increase in the number of lung
transplants over the past decade, the largest increase was
seen in patients over the age of 50 (more than doubling
between 1996 and 2005). The majority of transplant recip-
ients from 1996 through 2005 continue to be aged 50–64
years (58%, Figure 24). Changes between 2004 and 2005
were minimal for patients less than 35 years old as op-
posed to the older age groups. The percentage of deceased
donor lung transplants performed in females reached a
10-year low in 2005 at 45%, despite a larger percentage
of females on both the active and inactive waiting lists.
There have been no appreciable changes in the ethnicity
(87% white) or blood group type (44% Type O) distribu-
tion of recipients of deceased donor lung transplants since
1995.
The number of repeat lung transplants increased 2.2-fold
between 2004 and 2005 (from 33 to 74). See the accompa-
nying article in this report for further discussion of repeat
transplants (9). The number of bilateral lung transplants
has increased 112% since 1996, to 58% of transplants in
2005 from only 49% in 1996. Emphysema and chronic ob-
structive pulmonary disease (COPD) remain the most com-
mon diagnoses among lung transplant recipients; 33% of
Source: 2006 OPTN/SRTR Annual Report, Tables 12.4a.
Figure 24: Age distribution of deceased donor lung transplant
recipients, 1996–2005.
Source: 2006 OPTN/SRTR Annual Report, Tables 12.4a.
Figure 25: Primary diagnosis of deceased donor lung trans-
plant recipients, 1996–2005.
all transplants were performed for these indications. IPF
(28%) and cystic fibrosis (CF) (14%) were the next most
common diagnoses in 2005. All three of these diagnosis
groups have seen either similar or increased numbers of
transplants since 2004. That said, the distribution of diag-
noses has changed over the last decade and, in particu-
lar, since 2004 (Figure 25). Comparing Figures 20 and 25
shows that the decrease in the percentage of IPF patients
waiting for a lung has been accompanied by an increase in
the percentage of transplants performed on these patients.
Similarly, the increase in the percentage of patients with
COPD and emphysema on the waiting list has been accom-
panied by a decrease in the percentage of transplants per-
formed in these patients. These observations result from




Immunosuppression after lung transplantation has
changed significantly since 1995. Induction therapy was
used in 43% of all lung transplants performed in 2005,
whereas it was used in only 26% of lung transplants in
1996. The induction therapies used most commonly in
2005 were basiliximab (18%) and daclizumab (12%). In
1996, anti-thymocyte globulin induction therapy was used
in 23% of transplants and was by far the most common
therapy. In 2005, baseline therapy prior to discharge
included corticosteroids (98%), tacrolimus (Prograf®,
Astellas Pharma US) (76%) and an anti-metabolite, either
azathioprine (Imuran®, GlaxoWellcome, New Zealand)
(38%) or MMF (Cellcept®, Roche) (51%). Calcineurin
inhibitor use has changed dramatically—from cyclosporine
(Neoral® or Sandimmune, Novartis, East Hanover, NJ)
(71%) in 1996 to tacrolimus (76%) in 2005 . In 2004,
maintenance immunosuppression administered between
discharge and 1 year posttransplant was essentially the
same as immunosuppression prior to discharge, except
that the use of Sirolimus increased from 0.6% to 9%
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∗Adjusted to characteristics of transplants in 1995. Values past
2000 for 5- year, 2002 for 3- year, and 1995 for 10-year survival not
determined due to insufficient follow-up
Source: 2006 OPTN/SRTR Annual Report, Table 12. 13a.
Figure 26: Adjusted∗ short- and long-term deceased donor
lung patient survival, by year of transplant, 1993–2004.
of lung transplant cases. The immunosuppressive agent
most commonly used to treat acute rejection within the
first year after transplant was corticosteroids, which were
used in 94% of acute rejection cases.
Lung transplant outcomes
The average death rate in the first year after deceased
donor lung transplantation has been decreasing steadily
over the past 10 years, from 366 deaths per 1000 patient-
years at risk in 1996 to 168 deaths per 1000 patient-years at
risk in 2004. Adjusted to the age, race, gender and diagno-
sis characteristics of the 2003–2004 deceased donor lung
transplant population (3-month/1-year cohort), patient sur-
vival rates for deceased donor lung transplant recipients at
3 months, 1 year, 3 years and 5 years were 94%, 85%, 66%
and 51%, respectively. Adjusted patient survival rates for
both short- and long-term follow-up have improved since
1996 (Figure 26).
Since 1996, the highest first-year death rate has generally
been in the group of recipients aged 65 years and over,
who had a rate of 254 deaths per 1000 patient-years at
risk among 2004 recipients (Figure 27). The older patients
also had a slightly lower 5-year survival rate, adjusted for
Source: 2006 OPTN/SRTR Annual Report, Table 12. 7a.
Figure 27: Annual death rates per 1000 patient-years at risk,
by age group, 1996–2004.
Source: 2006 OPTN/SRTR Annual Report, Table 12. 7a.
Figure 28: Annual death rates during first year after deceased
donor lung transplant, by primary diagnosis, 1996–2004.
other patient characteristics, when compared to younger
recipients. Death rates in the group aged 35–49 and 50–
64 have been generally decreasing over the past 10 years
(from 381 and 388 for transplants performed in 1996 to
140 and 172 for those performed in 2004, respectively).
The trend in the 18–34-year-olds is less clear but may be
showing a decrease.
First-year death rates per 1000 patient-years at risk among
ethnic groups in 2004 were lowest for whites at 165, fol-
lowed by Hispanic/Latinos at 177 and African American at
217; there has been some year-to-year variability in this or-
dering over the past decade. Asians seem to have better
3- and 5-year patient survival rates than other race groups
but the number of patients in this group is small (83% vs.
61–74% at 3 years, and 61% vs. 38–52% at 5 years ad-
justed to the age, gender and diagnosis characteristics of
the 2003–2004 deceased donor lung transplant recipient
population).
The first-year death rates per 1000 patient-years at risk
by gender in 2004 were 10% higher for females at 175
than for males at 160; this was the first time during the
past 10 years that females had a higher death rate than
males. Females had an approximate 1–2 percentage point
disadvantage in terms of survival at 3 months, 1 year, 3
years and 5 years.
Lung transplant recipients who had received a previous
transplant had a higher death rate than first-time recipients
(427 vs. 161 per 1000 patient-years at risk) and lower un-
adjusted graft survival at 3 months, 1 year, 3 years and
5 years (79%, 59%, 43% and 23%, respectively). In ad-
dition, recipients who were hospitalized, admitted to an
intensive care unit, or on life support had a higher an-
nual death rate in the first year after transplantation (234,
769 and 371 deaths per 1000 patient-years at risk, respec-
tively). Recipients with an underlying diagnosis of primary
pulmonary hypertension (PPH) continued to have the high-
est death rate in the first year after transplantation (267
per 1000 patient-years) compared to recipients with other
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diagnoses. They were followed by recipients with IPF,
CF and emphysema/COPD (235, 146 and 132 per 1000
patient-years, respectively) (Figure 28). This order is re-
peated when looking at 1-year survival adjusted for other
patient characteristics (PPH: 77%, IPF: 81%, CF: 85% and
emphysema/COPD: 88%), although 5-year adjusted sur-
vival is more comparable for these diagnosis groups (PPH:
54%, IPF: 48%, CF: 51% and emphysema/COPD: 52%,
adjusted to the age, gender and diagnosis characteristics
of the 2003–2004 deceased donor lung transplant recipient
population).
Centers with a volume greater than 21 transplants per year
had a higher 5-year graft and patient survival rate (53%
and 55%, respectively) than did lower-volume centers (42–
46% and 45–50%, respectively), where these percentages
are not adjusted for varying characteristics of patients in
centers. Recipients of lungs from donors aged 50–64 had
relatively lower unadjusted 5-year graft and patient survival
rates (44% and 45%, respectively). This was not true for
donors aged 65 and above, although the number of ac-
cepted organs from this age group is fairly small and may
have a bearing on organ quality.
In general, adjusted graft survival rates for the same time
intervals and recipient demographics are similar to adjusted
patient survival rates. The reason for the similarity in ad-
justed graft and patient survival rates is that lung retrans-
plantation is fairly uncommon (5% in 2005) so that the
two measure nearly the same thing. The reason that so
few patients receive second lung transplants has histor-
ically been that the outcomes are worse than outcomes
of first-time transplants and the ability to survive on the
waiting list for a second lung was a limiting factor, as well.
Long-term survival, not surprisingly, continues to improve
and while The International Society of Heart and Lung
Transplantation (ISHLT) composite survival at 5 years is
48%, a review of the SRTR data suggests that survival
at 5 years now approaches 55%.
Refinements in preservation techniques and acute and
chronic patient care continue to take place. This is re-
flected by the fact that the 3-month and 1-, 3- and 5-
year survival rates continue to improve. Furthermore, the
near universal adoption of low potassium dextran preser-
vation solutions appears to have safely extended cold is-
chemia times. SRTR data now suggest ischemia times can
comfortably be extended to 8 h. Furthermore, the inter-
action between older age and prolonged ischemia time
does not appear to have as strong an adverse effect as
was once believed, since the death rates with any given
donor age have declined as overall death rates have dec-
lined.
A significant change in clinical practice relates to the use of
donation after cardiac death (DCD) lungs. Anecdotal experi-
ence in the past encouraged widespread adoption of tech-
niques espoused at the Consensus Conference on DCD
in Philadelphia, PA, in April 2005. In 2005, the Organ Do-
nation Breakthrough Collaborative may have contributed
to an increase in DCD lung utilization. The technique for
DCD recovery is critical, requiring bronchoscopic clearance
of the subglottic larynx, as well as the tracheal bronchial
tree, immediately prior to extubation of the potential DCD
donor. The extubation needs to occur in the operating
room in order to have a meaningful chance for successful
recovery.
Lung allocation policy changes
The wave of change that followed initiation of the new
lung allocation system in May 2005 continues to be felt.
Overall, the size of the waiting list has decreased dramati-
cally and the ability to get patients transplanted sooner has
been enhanced significantly. However, refinements in the
lung allocation system will be possible when longitudinal
clinical and outcomes measures for transplant candidates
become available. Much of the work by the OPTN Tho-
racic Organ Transplantation Committee continues to focus
on such issues.
Patients with emphysema are transplanted less frequently
under the new system, perhaps reflecting an inability to
adequately estimate progression of disease. For example,
PaCO2 is not yet part of the LAS, whereas high and rising
PaCO2 are known to be predictive of a poor outcome with-
out intervention. Likewise, patients with pulmonary hyper-
tension also tend to have low LAS and it has been difficult
to track the factors that would appropriately increase their
scores, as clinical signs of right heart failure progress. At
this point, the OPTN Thoracic Committee plans to collect
more data at listing and every 6 months to analyze and to
help better predict outcomes.
Perhaps the next most significant policy change during
the last year has been the termination of all alternate
allocation schemes. Thus, all rules for allocation are na-
tional and not focused on smaller areas of distribution. As
patient acuity and potential benefit from transplantation
becomes clearer under the new lung allocation system,
patient needs will likely supersede center-specific demo-
graphics. Accordingly, regionalization of thoracic organs as
a transplant resource may be in the offing. Furthermore,
the safe extension of the cold ischemia times to 8 h im-
plies that broader geographic sharing is both ethical and
practical.
Overall, it seems that listed patients are now older, sicker
and more often hospitalized compared to previous years.
It is not yet clear whether transplants of sicker patients,
after shorter waiting times, will negatively affect out-
comes. Ethically, however, when the alternative for such
patients is death, it is difficult if not impossible to deny
them that opportunity. More retransplants are also being
done, despite the fact that acute, mid- and long-term out-
comes are significantly compromised for such patients.
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Whether or not this practice should continue to expand is
controversial and is more thoroughly discussed in an ac-
companying article in this report (9).
Double lung transplants are also increasing, justified by the
fact that after 1 year, the survival curves begin to separate
and show greater benefit for the double-lung recipients
compared to single-lung recipients. However, diagnosis-
specific advantages of single versus double transplanta-
tion are less well understood and are not addressed in this
Annual Report.
The practice of living donor lobar transplantation has de-
creased markedly. Between 15 and 29 of such operations
were done annually for the last 9 years, but in 2005 only one
patient received living donor lungs. The ability to transplant
patients sooner under the new lung allocation system has
most likely reduced the current demand for living donor
transplantation.
Survival after transplantation still varies by listing diagno-
sis. Patients with pulmonary hypertension have the poor-
est outcomes at 3 months and 1 year, while long-term out-
comes appear to be comparable to other listing diagnoses.
Transplant outcomes still correlate with center volume and
the clearest inflection point remains at 21 transplants per
year.
As the criteria for acceptable donor lungs are extended, it
appears beneficial to use lungs from donors over 65 years
of age. The ideal donor previously had been defined as 55
years of age or younger, but 3 month and 1-, 3- and 5-
year survival among recipients who received donor organs
from patients over 65 years of age were similar to those
receiving organs from younger donors. It should be noted,
however, that the number of donors in this age group is
small. Long-term survival, not surprisingly, continues to im-
prove and while the ISHLT composite survival at 5 years is
48%, a review of the SRTR data suggests that survival at
5 years is comfortably in excess of 50% and may be close
to 55%.
Improved knowledge about the safe use of marginal lungs,
better preservation techniques and better communication
led to significant increases in the number of transplants
performed over the last 12 months. This has been a na-
tional trend, but there have also been particular pockets of
growth in certain areas of the country including California,
Florida, Pennsylvania and Washington.
Heart-Lung
For the seventh consecutive year, the number of pa-
tients on the active waiting list for a heart-lung trans-
plant decreased to a 10-year low of 45 patients in 2005
(Figure 29). These numbers are very small compared to the
Source: 2006 OPTN/SRTR Annual Report, Table 13. 1a and 13.4.
Figure 29: Number of heart-lung patients active on waiting
list at year-end and number of heart-lung transplants, 1996–
2005.
nearly 3000 candidates on the waiting list for heart and over
3000 candidates on the waiting list for lung. The reason for
the decline in the number of active waiting list patients is
unclear, but difficulty in obtaining a combined heart-lung
block and the relatively poor post-transplant survival, both
in the short and long term, could be factors, especially com-
bined with the shift toward use of double-lung transplants
and improved overall survival in lung transplantation.
The 25th percentile of time to transplant decreased to a
10-year low of 100 days in 2005, which is longer than for
lung transplant candidates, a 65% decrease from 284 days
in 2004.
Heart-lung recipient characteristics
There were only 33 heart-lung transplants performed in
2005, a decline from a high of 62 in 1997. The most com-
mon diagnoses were PPH and congenital heart disease.
Heart-lung recipient outcomes
The SRTR database identifies 57 transplant centers that
performed heart-lung transplants at some point between
1996 and 2005. However, 60% of these centers did not
perform a combined transplant in 2005.
The death rate in the first year posttransplant, reported per
1000 patient-years at risk, was down to a 10-year low at
301 for recipients with transplants in 2004. However, these
estimates are based on very few patients.
On the clinical front, heart-lung replacement continues to
have a small but important place in thoracic transplantation
in the United States, with 32 cases done in 2005. While
there has been a general decline in the number of regis-
trants for heart-lung transplants, the operation will still have
a role in the care of patients with combined heart and lung
failure and especially vascular diseases, such as idiopathic
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pulmonary arterial hypertension and congenital heart dis-
eases with secondary pulmonary hypertension.
As with lung transplantation, heart-lung transplantation has
seen an apparent decrease in both the number of regis-
trants and in the time to transplantation. The causes of
this are likely multifactorial, possibly including implemen-
tation of the new Lung Allocation System and the Organ
Donation Breakthrough Collaborative.
Following in the wakes of both lung and heart transplanta-
tion, the management of heart-lung patients has evolved
to incorporate newer immunosuppressants. The trend has
moved toward broader usage of tacrolimus rather than
cyclosporine A, and MMF instead of azathioprine. These
trends become stronger by the first year after transplant.
The trend for induction immunosuppression follows that of
lung transplantation, with the use of IL-2R inhibitors out-
weighing the use of anti-lymphocyte and anti-thymocyte
preparations, while alemtuzumab (Campath) was used a
small minority of the time.
The biggest news in heart-lung transplantation has been
the start of the Lung Allocation System in May 2005. In
this system, all recipients are categorized by clinical criteria
and a priority score for lung allocation is calculated, balanc-
ing risk of death without transplant against the predicted
outcome with transplantation. As with other multi-organ
operations, the heart-lung candidate gets offers as he or
she becomes eligible for either organ. The experience has
so far been limited, but early mortality figures suggest that
current practice has not hurt outcomes. Caution needs to
be used in interpreting the data, because the waiting list
is much different from in the past, with far fewer patients
being listed early, while some who are very ill may now get
organ offers despite very short wait times. This may have
the tendency to decrease waiting list deaths, while seem-
ing to raise the risk of postoperative mortality. A longer pe-
riod of observation is warranted to assess the real effect
of the LAS on outcomes.
Conclusion
Over the last 10 years, we have seen major shifts in
patient-care practices, as well as stunning advances in pol-
icy implementation. Heart transplants are performed less
frequently than in the past, while lung transplants have
never been more numerous. Heart-lung transplants con-
tinue to play a small role in total thoracic transplants. Each
of these changes has been the result of continuous im-
provement in management of advanced diseases coupled
with thoughtful policy implementation. The overall picture
of thoracic transplantation is clear: improvements continue
to evolve for the benefit of patients throughout the United
States.
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